In the end of that development I see a bottomed stock with a small float which can do a quick reversal...
What’s the upside in reverse stock split? Meeting Nasdaq listing requirements?
Brokers sold 15% of float short prior to placement at higher prices and now dropped bid to .90c
Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering
2023-07-27 21:31 ET - News Release
CHATHAM, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,000,000 shares of common stock in a public offering at a combined offering price of $1.00 per share (or common stock equivalents in lieu thereof) and accompanying warrant. The warrants have an exercise price of $1.00 per share, will become exercisable commencing the date of issuance, and will expire five years following the issuance date. The closing of the public offering is expected to take place on or about August 1, 2023, subject to the satisfaction of customary closing conditions.
The gross proceeds of the offering will be approximately $7 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, the build out of the Company’s manufacturing and research and development facilities, and the acquisition or licensing of approved products and products in development.
A.G.P./Alliance Global Partners is acting as lead placement agent for the offering.
Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254975) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Tonix may file with the SEC. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at email@example.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Tonix has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Tonix and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia, nearing complete enrollment in a potentially registration-enabling study, with topline data expected in the fourth quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 study has been completed, and topline results are expected in the third quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets), a once-daily formulation being developed as a treatment for major depressive disorder (MDD), is nearing complete enrollment with topline results expected in the fourth quarter of 2023. TNX-4300 (estianeptine) is a small molecule oral therapeutic in preclinical development to treat MDD, Alzheimer’s disease and Parkinson’s disease. TNX-1900 (intranasal potentiated oxytocin), in development for chronic migraine, is currently enrolling with topline data expected in the fourth quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the third quarter of 2023. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, classes of broad-spectrum small molecule oral antivirals.
* Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.
Tonix Medicines has contracted to acquire the Zembrace SymTouch and Tosymra registered trademarks. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc.
Tonix had great news on 5/17 - huge potential
Tianeptine is approved for depression and anxiety in Europe, Asia and South America. It works as well as other antidepressants without the side effects of sexual dysfunction and weight gain. It also may help Bipolar, Parkinson’s and Alzheimer’s.
Our CEO Lis presenting data at a conference this week. Stephen Stahl quoted in above article is one of the best Psychopharmacologists in the country.
I am a Psychiatrist attending the APA convention in SF. 2 other prominent Psychiatrists talked about Tianeptine today and one of them told me that he gets it from Europe for his patients.
My question is: if this drugs has been approved for many years in Europe and is generic, how can Tonix get a patent to sell it as a brand name drug?
I doubled down after the RS. Avoiding delisting with less shares outstanding, we are set up for a huge run on good news.
You nailed it!
You meant that the CEO will Rapidly Dilute the Endless New FREE shares Super-Heavily until TNXP hits a New Bottom $0.1?
It seems that we might see its Real Bottom $0.28 again in the coming days/weeks...
Anyway TNXP performs Very Similarly (5.6-Bagger rally) with its Bio-Med-Tech peer (PBH*: 5.2-Bagger rally) though its Top MV ($90,331,980.01) is Much Much Much Much Much Higher than the Top MV ($25,272,500.00) of its peer!
Did TNXP’s peer bleed 9% today?
What “peer”? Another heavily promoted scam?
Do you know what kinds of the other Terrible things the CEO did to the company or stock beside the Endless Super Heavy Dilutions and Repeated Big R/S? Is he the only reason for TNXP to crash down to $0.1? I wish no more Big R/S in the future anyway! So far TNXP only crashed down to $0.28! So, it is still Long way to go before it hits $0.1...
At your-predicted Target $0.1 the MV of TNXP (5.4-Bagger) will be $5,753,629.30 which corresponding to the Same MV of its Very-Similar-performance peer (5.2-Bagger) at $0.00125215 v.s. at Mere $0.0002 now! At the Top $1.57 the MV of TNXP is $90,331,980.01 which corresponding to the Same MV of its peer at $0.01965876 which is 3.57432 Times of its Top $0.0055!
What biotech pink sheet “peer”?
TNXP is very similar to other stocks that trade on the scam OTC?
No doubt, those Super Stupid And Hyper Greedy TNXP-shorters were Super Painful with Hyper Losses when they saw TNXP soar 5.4-Bagger to $1.57 from the FAKE Bottom $0.289, just like its Bio-Tech Pink-Sheet peer did Almost-the-Same performance (5.2-Bagger Huge rally --- from its previous Bottom $0.0005 to its most recent high $0.0026)!
Anyway at the Top this stock has Eye-Popping high $90,331,980 MV based on Very Old OS count v.s. its peer only has Mere $25,272,500 MV at Top!
wow. moving up and up and up.....
Wow, TNXP is heading onto the Same 5.2-Bagger Huge rally to hit $1.456 from its REAL Bottom $0.28 as its Bio-Tech Pink-Sheet peer (PBH*) did --- from previous Bottom $0.0005 to most recent high $0.0026!
TIZZUNI, good thing you got in before the TSUNAMI
Big up wave has just started
I was one of those stupid sellers but I bought back in today.
I'm wondering who are those very stupid sellers which dumped Tens Of Millions shares at $0.28 ~ $0.39 even after TNXP surged to $0.755 from $0.352? Anyway $1.08 might be broken out in the next wave of strong bounce...
Do you know the current OS count since the TA is Gagged for the SS? TIA!
Yea that,s pretty good.
TNXP hit $1 or Dollar Land today as I predicted! Because it is Super Undervalued (based on its Book Value and Cash Value) and Hyper Oversold (crashing to $0.28 from the Dollar Land)!
I'm very happy to have stolen Millions shares from $0.39 all the way down to $0.28xx by averaging down my cost base!
It might run the Same 5.2-Bagger Huge rally to hit $1.456 as its Bio-Tech Pink-Sheet peer did --- from its previous Bottom $0.0005 to its most recent high $0.0026...
Wow!, 25% gain today.
4 of my big holdings were under $1.00 in past few days. 3 of 4 are now over: SRNE, PLUR AND ATHX.
TNXP will be there soon. Maybe tomorrow. Doubled average daily volume.
Only need 18% gain from here after tripling from low
Why is it moving in your opinion?
I wouldn't buy TNXP with found money.
Wow, the Gains on TNXP are MASSIVE if anyone did follow me to buy this Hidden Gem all the way average down to the Real Bottom $0.28!
I'm very happy to see a strong 2.982143-Bagger Quick And Huge rally here! Today's high $0.835 could be broken out anyway...
We might see the Dollar Land again in the coming days/weeks...
I believe a lots of investors like myself have already made Huge And Quick profit from investing TNXP! If I were you then I would buy TNXP ASAP before it is too late...
I wouldn't buy TNXP with found money.
LOL, Gains on TNXP are MASSIVE if anyone did buy all the way average down to $0.28! Glad to see a strong 2.92-Bagger Quick Huge rally here! $0.8175 could be the Top anyway.
I believe a lots of investors like me have already made Huge profit from investing TNXP!
No thanks, I don't buy heavily promoted scams that trade on the OTC.
LOL, you're 100% wrong! TNXP has already Bottomed out at $0.28 (premarket-session-low) or $0.289 (regular-session-low)! It is heading onto $0.755 again...
Buy all the shares you could afford now and thank me later for huge profit!
No more Giant Downtrend! No more Huge R/S! No more Endless Super Heavy dilutions!
Had a stop order in at .3202 and sure enough it was hit in the first 5 minutes this morning. Nice close today though.
Barely holding above .30. Hope this moves north again.
And now it's back above .30. It was oversold so this could be the beginning of the turn-around we've been waiting for.
Well now it's trading under .30.